TriVascular, Inc. Announces The Closing Of Its Initial Public Offering

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SANTA ROSA, Calif., April 22, 2014 (GLOBE NEWSWIRE) -- TriVascular Technologies, Inc. (Nasdaq:TRIV), manufacturer of the Ovation Primeā„¢ Abdominal Stent Graft System, today announced the closing of its initial public offering of 7,475,000 shares of its common stock at a public offering price of $12.00 per share, including 975,000 shares sold pursuant to the underwriter's option to purchase additional shares. The company's shares began trading on The NASDAQ Global Select Market on April 16, 2014 under the ticker symbol "TRIV."

Help employers find you! Check out all the jobs and post your resume.

Back to news